Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study.
Journal of the American Academy of Dermatology（2023）
摘要
These findings underscore potential opportunities for dermatologists and oncologists in counseling and monitoring patients.
更多查看译文
关键词
cutaneous immune-related adverse events,cutaneous toxicities,immune checkpoint inhibitors,immunotherapy,melanoma,skin cancer,talimogene laherparepvec
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要